Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors

Open access
Sun, Linmao, Liu, Yufeng, Guo, Xinyu, Cui, Tianming, Wu, Chenghui, Tao, Jie, Cheng, Cheng, Chu, Qi, Ji, Changyong, Li, Xianying, Guo, Hongrui, Liang, Shuhang, Zhou, Huanran, Zhou, Shuo, Ma, Kun, Zhang, Ning, Wang, Jiabei, Liu, Yao, Liu, Lianxin · 2024 · Nature Communications

Abstract

Despite the importance of spliceosome core components in cellular processes, their roles in cancer development, including hepatocellular carcinoma (HCC), remain poorly understood. In this study, we uncover a critical role for SmD2, a core component of the spliceosome machinery, in modulating DNA damage in HCC through its impact on BRCA1/FANC cassette exons and expression. Our findings reveal that SmD2 depletion sensitizes HCC cells to PARP inhibitors, expanding the potential therapeutic targets. We also demonstrate that SmD2 acetylation by p300 leads to its degradation, while HDAC2-mediated deacetylation stabilizes SmD2. Importantly, we show that the combination of Romidepsin and Olaparib exhibits significant therapeutic potential in multiple HCC models, highlighting the promise of targeting SmD2 acetylation and HDAC2 inhibition alongside PARP inhibitors for HCC treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-024-49573-7

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 High expression of SmD2 is correlated with poor prognosis in HCC. a Schematic representation of the label-free quantitative proteomics analysis workflow performed on liver tumor and adjacent non-tumor tissue samples from six HCC patients. b the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the proteomics revealed the Spliceosome pathway to be the rank 2 significantly upregulated pathway. two-sided hypergeometric test, with P values adjusted for multiple comparisons using the Benjamini–Hochberg False Discovery Rate (FDR) method. c Gene Set Enrichment Analysis (GSEA) was used to analyze the Spliceosome gene signatures in the proteomic data of tumor and normal tissues; the Normalized Enrichment Score (NES) was used to measure the degree of enrichment. one-sided permutation test. d Volcano plot highlighting the significant upregulation of Sm proteins in HCC tumors (orange dots) with respect to normal tissue, with SmD2 showing the most pronounced increase in tumor/normal ratio of intensity. e Analysis of mRNA expression differences of 7 Sm proteins in tumor and normal tissues from 22 HCC patients. mean values ± SEM. f Representative immunohistochemical staining for SmD2 in two tissue microarrays (TMAs) of 106 HCC patients, showcasing an increased SmD2 expression in tumor regions compared to normal tissue. g Quantitative analysis of SmD2 staining intensity in two TMAs from 106 HCC patients, two-sided t-test. h Kaplan–Meier survival analysis using the median expression level of SmD2 to stratify cases into high and low SmD2 expression groups. Overall and disease-free survival curves are generated for each group and compared using the log-rank test. Analysis of two TMAs encompassing 106 HCC patients reveals that high SmD2 expression is associated with a poorer prognosis. Figure 1a created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. Source data are provided as a Source Data file.
Fig. 1 High expression of SmD2 is correlated with poor prognosis in HCC. a Schematic representation of the label-free quantitative proteomics analysis workflow performed on liver tumor and adjacent non-tumor tissue samples from six HCC patients. b the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the proteomics revealed the Spliceosome pathway to be the rank 2 significantly upregulated pathway. two-sided hypergeometric test, with P values adjusted for multiple comparisons using the Benjamini–Hochberg False Discovery Rate (FDR) method. c Gene Set Enrichment Analysis (GSEA) was used to analyze the Spliceosome gene signatures in the proteomic data of tumor and normal tissues; the Normalized Enrichment Score (NES) was used to measure the degree of enrichment. one-sided permutation test. d Volcano plot highlighting the significant upregulation of Sm proteins in HCC tumors (orange dots) with respect to normal tissue, with SmD2 showing the most pronounced increase in tumor/normal ratio of intensity. e Analysis of mRNA expression differences of 7 Sm proteins in tumor and normal tissues from 22 HCC patients. mean values ± SEM. f Representative immunohistochemical staining for SmD2 in two tissue microarrays (TMAs) of 106 HCC patients, showcasing an increased SmD2 expression in tumor regions compared to normal tissue. g Quantitative analysis of SmD2 staining intensity in two TMAs from 106 HCC patients, two-sided t-test. h Kaplan–Meier survival analysis using the median expression level of SmD2 to stratify cases into high and low SmD2 expression groups. Overall and disease-free survival curves are generated for each group and compared using the log-rank test. Analysis of two TMAs encompassing 106 HCC patients reveals that high SmD2 expression is associated with a poorer prognosis. Figure 1a created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 Impact of SmD2 deficiency on HCC progression. a Immunoblot demonstrating the effects of doxycycline (DOX) titration on EZ-Tet-pLKO-shSNRPD2 cells, with 72 hours of treatment followed by cell lysis. The experiment was repeated three times with similar results. WCL, Whole Cell Lysate. b Representative images of colony-formation assays of uninduced or DOX-induced shSNRPD2 expression across three HCC cell types. c Quantification of the colony formation assay (n = 3 biologically independent experiments) shown in b for three different cell lines. two-sided t-tests. d Representative confocal images of spheroid formation assays with DOX-induced SNRPD2 knockdown in HCC cell lines, stained with Phalloidin (to stain the cytoskeleton) and DAPI (to stain nuclei). e Quantitative analysis of spheroid diameters (n = 22 biologically independent samples) from the assay in d, showing a significant decrease in spheroid size with SNRPD2 knockdown across all three cell lines. two-sided t-tests. f Tumor growth of inducible shSNRPD2 HCCLM3 cells in male nude mice, with doxycycline (20 mg/kg) orally administered every other day to induce shSNRPD2 expression, beginning on day 7. Two-way ANOVA. g Representative images of tumor volumes from HCCLM3-harboring mice sacrificed on day 29. h Quantitative analysis of tumor (n = 11) volume and weight from (g). two-sided t-tests. i Schematic illustrating transposon- and CRISPR-Cas9-based hydrodynamic injection of vectors into mice via the tail vein to generate liver tumors resembling human HCC. The transposon-based vector overexpressing MYC can express luciferase. j Bioluminescence images of C57BL/6 mice (n = 10) at indicated time points after plasmid injection, indicating tumor burden over time. k Individual bioluminescence trajectories for each mouse over time, comparing non-targeting control to sg-SNRPD2. l Bioluminescence signal at indicated time points post plasmid injection in C57BL/6 mice (n = 10). two-sided t-tests. m Representative images of livers from j. n Kaplan–Meier survival curve of C57BL/6 mice treated as in j. log-rank test. Data are presented as mean values ± SEM. Figure 2i created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. Source data are provided as a Source Data file.
Fig. 2 Impact of SmD2 deficiency on HCC progression. a Immunoblot demonstrating the effects of doxycycline (DOX) titration on EZ-Tet-pLKO-shSNRPD2 cells, with 72 hours of treatment followed by cell lysis. The experiment was repeated three times with similar results. WCL, Whole Cell Lysate. b Representative images of colony-formation assays of uninduced or DOX-induced shSNRPD2 expression across three HCC cell types. c Quantification of the colony formation assay (n = 3 biologically independent experiments) shown in b for three different cell lines. two-sided t-tests. d Representative confocal images of spheroid formation assays with DOX-induced SNRPD2 knockdown in HCC cell lines, stained with Phalloidin (to stain the cytoskeleton) and DAPI (to stain nuclei). e Quantitative analysis of spheroid diameters (n = 22 biologically independent samples) from the assay in d, showing a significant decrease in spheroid size with SNRPD2 knockdown across all three cell lines. two-sided t-tests. f Tumor growth of inducible shSNRPD2 HCCLM3 cells in male nude mice, with doxycycline (20 mg/kg) orally administered every other day to induce shSNRPD2 expression, beginning on day 7. Two-way ANOVA. g Representative images of tumor volumes from HCCLM3-harboring mice sacrificed on day 29. h Quantitative analysis of tumor (n = 11) volume and weight from (g). two-sided t-tests. i Schematic illustrating transposon- and CRISPR-Cas9-based hydrodynamic injection of vectors into mice via the tail vein to generate liver tumors resembling human HCC. The transposon-based vector overexpressing MYC can express luciferase. j Bioluminescence images of C57BL/6 mice (n = 10) at indicated time points after plasmid injection, indicating tumor burden over time. k Individual bioluminescence trajectories for each mouse over time, comparing non-targeting control to sg-SNRPD2. l Bioluminescence signal at indicated time points post plasmid injection in C57BL/6 mice (n = 10). two-sided t-tests. m Representative images of livers from j. n Kaplan–Meier survival curve of C57BL/6 mice treated as in j. log-rank test. Data are presented as mean values ± SEM. Figure 2i created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 SmD2 depletion enhances the accumulation of DNA damage and sensitivity to PARP inhibitors in HCC. a Gene Ontology analysis of genes (n = 2636, p < 0.05) downregulated by inducible shSNRPD2 Knockdown in HCCLM3 cells, compared to control cells. b Gene Set Enrichment Analysis (GSEA) indicating that DNA repair pathways are significantly downregulated in HCC cells with SNRPD2 knockdown (DOX+) and in HCC samples from The Cancer Genome Atlas (TCGA) with low expression of SNRPD2 (coding SmD2). c Volcano plot of differentially expressed genes after DOX-induced SNRPD2 knockdown, with |Log2 (fold change)| = 0.5 and –log10(P-value) = 6 as thresholds; genes with y > 250 are shown as y = 250. Genes involved in DNA repair pathways such as FANCA, FANCD2, BRCA1 are notably downregulated. d Quantitative RT-PCR validation of RNA-seq data showing reduced mRNA levels of several DNA repair genes with SNRPD2 knockdown. (n = 4 independent experiments). e Immunoblot showing BRCA1, FANCA, FANCD2 and γH2A.X expression in inducible shSNRPD2 cells. The experiment was repeated three times with similar results. f DNA damage accumulation with or without silencing of SNRPD2 detected using γH2A.X immunostaining. g Percentage of cells with ≥10 γH2A.X foci/nucleus, analyzed in random cells (n = 5 independent experiments). h Levels of PARylation and PARP1 expression measured by immunoblot in inducible shSNRPD2 cells. The experiment was repeated three times with similar results. i Olaparib dose-response curves on inducible shSNRPD2 HCC cell lines over 72 hours (n = 4 biologically independent samples). j Representative 3D culture plot of transfected inducible shSNRPD2 HCCLM3 cells after DOX and Olaparib (IC20) treatment. k Diameter of the cell spheres (n = 22 biologically independent samples) counted from j. l Inducible shSNRPD2 HCCLM3 cells were seeded into male nude mice. Doxycycline (20 mg/kg, orally, daily) and Olaparib (50 mg/kg, intraperitoneally, daily) were administered from day 10. Each line represents an individual tumor. m Tumor volume reduction in HCCLM3 xenografts after inducible SNRPD2 knockdown and further inhibition by Olaparib treatment, with representative images. n Statistical analysis of tumor volume data from (m) (n = 5). Mean values ± SEM. Two-sided t-tests were used to determine statistical significance, **P = 0.0022, and ***P < 0.001. Source data are provided as a Source Data file.
Fig. 3 SmD2 depletion enhances the accumulation of DNA damage and sensitivity to PARP inhibitors in HCC. a Gene Ontology analysis of genes (n = 2636, p < 0.05) downregulated by inducible shSNRPD2 Knockdown in HCCLM3 cells, compared to control cells. b Gene Set Enrichment Analysis (GSEA) indicating that DNA repair pathways are significantly downregulated in HCC cells with SNRPD2 knockdown (DOX+) and in HCC samples from The Cancer Genome Atlas (TCGA) with low expression of SNRPD2 (coding SmD2). c Volcano plot of differentially expressed genes after DOX-induced SNRPD2 knockdown, with |Log2 (fold change)| = 0.5 and –log10(P-value) = 6 as thresholds; genes with y > 250 are shown as y = 250. Genes involved in DNA repair pathways such as FANCA, FANCD2, BRCA1 are notably downregulated. d Quantitative RT-PCR validation of RNA-seq data showing reduced mRNA levels of several DNA repair genes with SNRPD2 knockdown. (n = 4 independent experiments). e Immunoblot showing BRCA1, FANCA, FANCD2 and γH2A.X expression in inducible shSNRPD2 cells. The experiment was repeated three times with similar results. f DNA damage accumulation with or without silencing of SNRPD2 detected using γH2A.X immunostaining. g Percentage of cells with ≥10 γH2A.X foci/nucleus, analyzed in random cells (n = 5 independent experiments). h Levels of PARylation and PARP1 expression measured by immunoblot in inducible shSNRPD2 cells. The experiment was repeated three times with similar results. i Olaparib dose-response curves on inducible shSNRPD2 HCC cell lines over 72 hours (n = 4 biologically independent samples). j Representative 3D culture plot of transfected inducible shSNRPD2 HCCLM3 cells after DOX and Olaparib (IC20) treatment. k Diameter of the cell spheres (n = 22 biologically independent samples) counted from j. l Inducible shSNRPD2 HCCLM3 cells were seeded into male nude mice. Doxycycline (20 mg/kg, orally, daily) and Olaparib (50 mg/kg, intraperitoneally, daily) were administered from day 10. Each line represents an individual tumor. m Tumor volume reduction in HCCLM3 xenografts after inducible SNRPD2 knockdown and further inhibition by Olaparib treatment, with representative images. n Statistical analysis of tumor volume data from (m) (n = 5). Mean values ± SEM. Two-sided t-tests were used to determine statistical significance, **P = 0.0022, and ***P < 0.001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 Analysis of SmD2-mediated alternative splicing in DNA repair genes. a Differences in rMATS inclusion values in inducible shSNRPD2 HCCLM3 cells (n = 3/group biologically independent samples) after doxycycline (DOX) treatment are presented as median values, where the center line in each box represents the median, the edges of the boxes represent the first (25th percentile) and third (75th percentile) quartiles, and the whiskers extend to the minimum and maximum values. A5SS, alternative 5’ splicing site; A3SS, alternative 3’ splicing site; RI, retained introns; SE, skipped exons; MXE, mutually exclusive exons.” b A half-volcano plot showing SE events in DNA repair genes is highlighted, where an inclusion value difference < −0.01 and –log10(P-value) = 2 were used as thresholds, and events with y > 16 are shown as y = 16. c, Visualizations of RNA-seq profiles (sashimi plots) of DNA repair genes. d RT-PCR validation of alternative splicing events in BRCA1, FANCA, FANCD2, FANCG, and FANCI genes, with GADPH as a loading control. Numbers in white boxs indicate exon skipping. The experiment was repeated three times with similar results. e Immunoblot analysis of SmD2 depletion HCCLM3 cells transduced with shUPF1. The experiment was repeated three times with similar results. Half-life of BRCA1 transcripts with exon 9 skipping (f), FANCA transcripts with exon 37 skipping (g), and FANCD2 transcripts with exon 30 skipping (h) were measured by qPCR (n = 4 biologically independent samples). i qPCR examining the changes of spliceosomal snRNAs in HCCLM3 cells after DOX-induced SmD2 knockdown (n = 4 biologically independent samples). j U1 snRNA binding energy for 5’ splicing sites (5’ss) in skipped exons (n = 9580) influenced by SNRPD2 knockdown compared to constitutive exons (n = 200,234). The central line in each box indicates the median of the dataset, with the box edges representing the 25th and 75th percentiles. The whiskers span from the minimum to the maximum data points, without any points classified as outliers. k Inducible shSNRPD2 HCCLM3 cells were transfected with wild-type (WT) miniBRCA1 or with minigenes harboring mutations in the 5′ss, which were analyzed with RT–PCR assays to quantify the percent exon inclusion. Mutations that strengthen the 5′ss reduce the effects of SNRPD2 knockdown on miniBRCA1 SE. (ψ) Pseudouridine. The experiment was repeated three times with similar results. Mean values ± SD. Two-sided t-tests, **P = 0.002288, and ***P < 0.001. Source data are provided as a Source Data file.
Fig. 4 Analysis of SmD2-mediated alternative splicing in DNA repair genes. a Differences in rMATS inclusion values in inducible shSNRPD2 HCCLM3 cells (n = 3/group biologically independent samples) after doxycycline (DOX) treatment are presented as median values, where the center line in each box represents the median, the edges of the boxes represent the first (25th percentile) and third (75th percentile) quartiles, and the whiskers extend to the minimum and maximum values. A5SS, alternative 5’ splicing site; A3SS, alternative 3’ splicing site; RI, retained introns; SE, skipped exons; MXE, mutually exclusive exons.” b A half-volcano plot showing SE events in DNA repair genes is highlighted, where an inclusion value difference < −0.01 and –log10(P-value) = 2 were used as thresholds, and events with y > 16 are shown as y = 16. c, Visualizations of RNA-seq profiles (sashimi plots) of DNA repair genes. d RT-PCR validation of alternative splicing events in BRCA1, FANCA, FANCD2, FANCG, and FANCI genes, with GADPH as a loading control. Numbers in white boxs indicate exon skipping. The experiment was repeated three times with similar results. e Immunoblot analysis of SmD2 depletion HCCLM3 cells transduced with shUPF1. The experiment was repeated three times with similar results. Half-life of BRCA1 transcripts with exon 9 skipping (f), FANCA transcripts with exon 37 skipping (g), and FANCD2 transcripts with exon 30 skipping (h) were measured by qPCR (n = 4 biologically independent samples). i qPCR examining the changes of spliceosomal snRNAs in HCCLM3 cells after DOX-induced SmD2 knockdown (n = 4 biologically independent samples). j U1 snRNA binding energy for 5’ splicing sites (5’ss) in skipped exons (n = 9580) influenced by SNRPD2 knockdown compared to constitutive exons (n = 200,234). The central line in each box indicates the median of the dataset, with the box edges representing the 25th and 75th percentiles. The whiskers span from the minimum to the maximum data points, without any points classified as outliers. k Inducible shSNRPD2 HCCLM3 cells were transfected with wild-type (WT) miniBRCA1 or with minigenes harboring mutations in the 5′ss, which were analyzed with RT–PCR assays to quantify the percent exon inclusion. Mutations that strengthen the 5′ss reduce the effects of SNRPD2 knockdown on miniBRCA1 SE. (ψ) Pseudouridine. The experiment was repeated three times with similar results. Mean values ± SD. Two-sided t-tests, **P = 0.002288, and ***P < 0.001. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 Mechanism of p300/HDAC2-mediated regulation of SmD2. a Immunoprecipitation coupled with mass spectrometry analysis was used to identify SmD2-interacting proteins in HCCLM3 cells (blue arrow indicates SmD2 signal). b Mass spectrometry spectrum showing the peptide of p300. c Co-immunoprecipitation of exogenous SmD2 and p300 in HEK293T cells after transfection with the indicated plasmids. d Immunofluorescence analysis to detect colocalization of SmD2 and p300 in HCCLM3 cells. The experiment was repeated three times with similar results. e Immunoblot to detect the acetylation of endogenous SmD2 in HCCLM3 cells treated with the SIRT inhibitor (5 mM NAM) or the HDAC inhibitor (1 μM TSA) overnight. Ac-K, acetylated lysine. f Immunoblot to detect the acetylation of exogenous HA-SmD2 in HEK293T cells treated with TSA or NAM. g Immunoblot of input and anti-HA immunoprecipitates (IPs) derived from HEK293T cells transfected with HA-SmD2 and Flag-tagged GCN5, PCAF, TIP60, CBP, or p300. h Immunoblot of input and anti-HA IPs derived from HEK293T cells transduced with HA-SmD2 and shp300. i Immunoblot of SmD2 changes from HCCLM3 cells after EP300 depletion. j Immunoblot to detect the acetylation of exogenous SmD2 from HCCLM3 cells treated with FDA-approved HDAC inhibitors overnight. k Expression levels of SmD2 and γH2A.X from HCCLM3 treated with the HDAC inhibitors. WCL, whole cell lysate. l Immunoblot of input and anti-HA IPs transfected with HA-SmD2 and Flag-tagged HDAC1 or HDAC2. m Immunoblot of input and anti-HA IPs transduced with HA-SmD2 and shHDAC2. n Immunoblot of SmD2 changes from HCCLM3 cells after HDAC2 depletion. o Positive correlations of SNRPD2 (encoding SmD2) mRNA levels with HDAC2 mRNA levels in TCGA-LIHC dataset (n = 424, 374 of which were tumor samples and 50 adjacent normal tissues. r Pearson’s correlation coefficient, two-tailed t-distribution test). p Kaplan–Meier analysis of HCC patients from TCGA, stratified by HDAC2 mRNA expression levels. Patients are categorized into two cohorts: those with HDAC2 expression above the median and those with expression below the median. q Tumor growth of inducible shHDAC2 HCCLM3 cells in nude mice, with doxycycline orally administered, beginning on day 5. 2way ANOVA. r Representative images of tumor from HCCLM3-harboring mice. s Quantitative analysis of tumor (n = 10) volume and weight from (r). Mean values ± SEM. two-sided t-tests. Each Western blot was independently repeated three times. Source data are provided as a Source Data file.
Fig. 5 Mechanism of p300/HDAC2-mediated regulation of SmD2. a Immunoprecipitation coupled with mass spectrometry analysis was used to identify SmD2-interacting proteins in HCCLM3 cells (blue arrow indicates SmD2 signal). b Mass spectrometry spectrum showing the peptide of p300. c Co-immunoprecipitation of exogenous SmD2 and p300 in HEK293T cells after transfection with the indicated plasmids. d Immunofluorescence analysis to detect colocalization of SmD2 and p300 in HCCLM3 cells. The experiment was repeated three times with similar results. e Immunoblot to detect the acetylation of endogenous SmD2 in HCCLM3 cells treated with the SIRT inhibitor (5 mM NAM) or the HDAC inhibitor (1 μM TSA) overnight. Ac-K, acetylated lysine. f Immunoblot to detect the acetylation of exogenous HA-SmD2 in HEK293T cells treated with TSA or NAM. g Immunoblot of input and anti-HA immunoprecipitates (IPs) derived from HEK293T cells transfected with HA-SmD2 and Flag-tagged GCN5, PCAF, TIP60, CBP, or p300. h Immunoblot of input and anti-HA IPs derived from HEK293T cells transduced with HA-SmD2 and shp300. i Immunoblot of SmD2 changes from HCCLM3 cells after EP300 depletion. j Immunoblot to detect the acetylation of exogenous SmD2 from HCCLM3 cells treated with FDA-approved HDAC inhibitors overnight. k Expression levels of SmD2 and γH2A.X from HCCLM3 treated with the HDAC inhibitors. WCL, whole cell lysate. l Immunoblot of input and anti-HA IPs transfected with HA-SmD2 and Flag-tagged HDAC1 or HDAC2. m Immunoblot of input and anti-HA IPs transduced with HA-SmD2 and shHDAC2. n Immunoblot of SmD2 changes from HCCLM3 cells after HDAC2 depletion. o Positive correlations of SNRPD2 (encoding SmD2) mRNA levels with HDAC2 mRNA levels in TCGA-LIHC dataset (n = 424, 374 of which were tumor samples and 50 adjacent normal tissues. r Pearson’s correlation coefficient, two-tailed t-distribution test). p Kaplan–Meier analysis of HCC patients from TCGA, stratified by HDAC2 mRNA expression levels. Patients are categorized into two cohorts: those with HDAC2 expression above the median and those with expression below the median. q Tumor growth of inducible shHDAC2 HCCLM3 cells in nude mice, with doxycycline orally administered, beginning on day 5. 2way ANOVA. r Representative images of tumor from HCCLM3-harboring mice. s Quantitative analysis of tumor (n = 10) volume and weight from (r). Mean values ± SEM. two-sided t-tests. Each Western blot was independently repeated three times. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 Romidepsin enhances the sensitivity of HCC to PARP inhibitors. a Dose-response curves for Olaparib in HCC cell lines following treatment with IC20 of Romidepsin (n = 4 biologically independent samples). b Synergistic dose-response curves for HCCLM3 cells treated with varying concentrations of Olaparib and Romidepsin (n = 4 biologically independent samples). c Combination index (CI) versus fraction affected for Olaparib and Romidepsin in HCCLM3 cells, derived from data in b (n = 4 biologically independent samples). d HCCLM3 tumors were dissected from the nude mice treated with vehicle, Olaparib, Romidepsin, or both (n = 5/group). e Quantitative analysis of tumor (n = 5) volume from d. f As d, but for Hepa1-6 tumor-bearing C57/BL6 mice (n = 6/group). g Quantitative analysis of tumor (n = 6) volume from f. h Schematic diagram of murine MYC-driven HCCs. After mating of H11LSL-Myc mice harboring a CAG promoter-loxp-STOP-loxp-Myc-polyA conditional overexpression structure at the H11 locus with Alb-cre mice for two months, the spontaneous development of HCC was observed. Subsequently, these murine HCCs were transplanted into the subcutaneous tissues for treatment. i As d, but for MYC-driven HCC tumor-bearing C57/BL6 mice (n = 5/group). j Quantitative analysis of tumor (n = 5) volume from i. k Schematic diagram of human HCC PDX. l As d, but for HCC PDX tumor-bearing NSG mice (n = 8/group). m Quantitative analysis of tumor (n = 8) volume from l. Mean values ± SEM. Two-sided t-tests. Figures h and k created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. Source data are provided as a Source Data file.
Fig. 6 Romidepsin enhances the sensitivity of HCC to PARP inhibitors. a Dose-response curves for Olaparib in HCC cell lines following treatment with IC20 of Romidepsin (n = 4 biologically independent samples). b Synergistic dose-response curves for HCCLM3 cells treated with varying concentrations of Olaparib and Romidepsin (n = 4 biologically independent samples). c Combination index (CI) versus fraction affected for Olaparib and Romidepsin in HCCLM3 cells, derived from data in b (n = 4 biologically independent samples). d HCCLM3 tumors were dissected from the nude mice treated with vehicle, Olaparib, Romidepsin, or both (n = 5/group). e Quantitative analysis of tumor (n = 5) volume from d. f As d, but for Hepa1-6 tumor-bearing C57/BL6 mice (n = 6/group). g Quantitative analysis of tumor (n = 6) volume from f. h Schematic diagram of murine MYC-driven HCCs. After mating of H11LSL-Myc mice harboring a CAG promoter-loxp-STOP-loxp-Myc-polyA conditional overexpression structure at the H11 locus with Alb-cre mice for two months, the spontaneous development of HCC was observed. Subsequently, these murine HCCs were transplanted into the subcutaneous tissues for treatment. i As d, but for MYC-driven HCC tumor-bearing C57/BL6 mice (n = 5/group). j Quantitative analysis of tumor (n = 5) volume from i. k Schematic diagram of human HCC PDX. l As d, but for HCC PDX tumor-bearing NSG mice (n = 8/group). m Quantitative analysis of tumor (n = 8) volume from l. Mean values ± SEM. Two-sided t-tests. Figures h and k created with BioRender.com, released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

See all 22

Metadata

Authors
Sun, L., Liu, Y., Guo, X., Cui, T., Wu, C., Tao, J., Cheng, C., Chu, Q., Ji, C., Li, X., Guo, H., Liang, S., Zhou, H., Zhou, S., Ma, K., Zhang, N., Wang, J., Liu, Y., & Liu, L.
Affiliations
University of Science and Technology of China (CN)
Corresponding author
Wang, Jiabei
Venue
Nature Communications
Published
2024-06-18
Volume
15
Issue
1
Pages
5209-5209
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4399766604
Cited by
18
References
75
Citations by year
2026: 7 · 2025: 9 · 2024: 2
FWCI
2.44
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (U19A2008)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
hepatocellular carcinoma, spliceosome, protein acetylation, P300, HDAC2, DNA damage response, PARP inhibitors, olaparib, romidepsin, protein stability, combination therapy
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Acetylation, Animals, DNA Damage, Exons, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Phthalazines, Piperazines, Gene Expression Regulation, Neoplastic, Spliceosomes, BRCA1 Protein, Cell Line, Tumor, Depsipeptides, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors. https://app.cochat.ai/papers/10.1038/s41467-024-49573-7
The paper
Sun, L., Liu, Y., Guo, X., Cui, T., Wu, C., Tao, J., Cheng, C., Chu, Q., Ji, C., Li, X., Guo, H., Liang, S., Zhou, H., Zhou, S., Ma, K., Zhang, N., Wang, J., Liu, Y., & Liu, L. (2024). Acetylation-dependent regulation of core spliceosome modulates hepatocellular carcinoma cassette exons and sensitivity to PARP inhibitors. Nature Communications. https://doi.org/10.1038/s41467-024-49573-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.